PT97991B - Processo para a preparacao de derivados de 2-(aminoalquil)-5-(arilalquil)-1,3-dioxanos e de composicoes farmaceuticas que os contem - Google Patents
Processo para a preparacao de derivados de 2-(aminoalquil)-5-(arilalquil)-1,3-dioxanos e de composicoes farmaceuticas que os contem Download PDFInfo
- Publication number
- PT97991B PT97991B PT97991A PT9799191A PT97991B PT 97991 B PT97991 B PT 97991B PT 97991 A PT97991 A PT 97991A PT 9799191 A PT9799191 A PT 9799191A PT 97991 B PT97991 B PT 97991B
- Authority
- PT
- Portugal
- Prior art keywords
- general formula
- naphthalenyl
- preparation
- mmoles
- group
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 19
- 238000002360 preparation method Methods 0.000 title claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 49
- -1 1-naphthalenyl group Chemical group 0.000 claims description 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 150000002009 diols Chemical class 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- NBGJZOKVOQQYEC-UHFFFAOYSA-N n-[3-(5-naphthalen-1-yl-1,3-dioxan-2-yl)propyl]acetamide Chemical compound C1OC(CCCNC(=O)C)OCC1C1=CC=CC2=CC=CC=C12 NBGJZOKVOQQYEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims 3
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 70
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 56
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 239000011541 reaction mixture Substances 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 238000010992 reflux Methods 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- 239000003610 charcoal Substances 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 235000007836 Chlorogalum pomeridianum Nutrition 0.000 description 3
- 240000006670 Chlorogalum pomeridianum Species 0.000 description 3
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 229940035437 1,3-propanediol Drugs 0.000 description 2
- QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- BWBVCAXBRMQDJU-UHFFFAOYSA-N diethyl 2-naphthalen-1-ylpropanedioate Chemical compound C1=CC=C2C(C(C(=O)OCC)C(=O)OCC)=CC=CC2=C1 BWBVCAXBRMQDJU-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PRPINYUDVPFIRX-UHFFFAOYSA-N 1-naphthaleneacetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CC=CC2=C1 PRPINYUDVPFIRX-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- ZIIYZLYOXZGOIL-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-methylpropanedioic acid Chemical compound OC(=O)C(C)(C(O)=O)C1=CC=C(Cl)C=C1 ZIIYZLYOXZGOIL-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- AISCQUJSWJBKSM-UHFFFAOYSA-N 2-naphthalen-1-ylpropane-1,3-diol Chemical compound C1=CC=C2C(C(CO)CO)=CC=CC2=C1 AISCQUJSWJBKSM-UHFFFAOYSA-N 0.000 description 1
- AWTNTUCOOBVVQI-UHFFFAOYSA-N 3-(5-naphthalen-1-yl-1,3-dioxan-2-yl)propan-1-amine;hydrochloride Chemical compound Cl.C1OC(CCCN)OCC1C1=CC=CC2=CC=CC=C12 AWTNTUCOOBVVQI-UHFFFAOYSA-N 0.000 description 1
- GFLPSABXBDCMCN-UHFFFAOYSA-N 4,4-diethoxybutan-1-amine Chemical compound CCOC(OCC)CCCN GFLPSABXBDCMCN-UHFFFAOYSA-N 0.000 description 1
- GZYGWTRPHYTZLR-UHFFFAOYSA-N 4-oxohexa-2,5-dienal Chemical compound C=CC(=O)C=CC=O GZYGWTRPHYTZLR-UHFFFAOYSA-N 0.000 description 1
- IOIIFUWXIINNKX-UHFFFAOYSA-N 5-(5-chloro-2-ethoxyphenyl)-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCc1nn(C)c2c1[nH]c(nc2=O)-c1cc(Cl)ccc1OCC IOIIFUWXIINNKX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000699729 Muridae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000000573 anti-seizure effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003179 convulsant agent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- DLJUSKDSLZYVSB-UHFFFAOYSA-N diethyl 2-(6-methoxynaphthalen-1-yl)propanedioate Chemical compound COC1=CC=C2C(C(C(=O)OCC)C(=O)OCC)=CC=CC2=C1 DLJUSKDSLZYVSB-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- GZXSDYYWLZERLF-UHFFFAOYSA-N ethyl n-ethylcarbamate Chemical compound CCNC(=O)OCC GZXSDYYWLZERLF-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- QENHCSSJTJWZAL-UHFFFAOYSA-N magnesium sulfide Chemical compound [Mg+2].[S-2] QENHCSSJTJWZAL-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- YGEAEJNJEVNVLG-UHFFFAOYSA-N n-(2,2-dimethoxyethyl)acetamide Chemical compound COC(OC)CNC(C)=O YGEAEJNJEVNVLG-UHFFFAOYSA-N 0.000 description 1
- ANONYJUYWUFMOA-UHFFFAOYSA-N n-(4,4-diethoxybutyl)acetamide Chemical compound CCOC(OCC)CCCNC(C)=O ANONYJUYWUFMOA-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- KVNYFPKFSJIPBJ-UHFFFAOYSA-N ortho-diethylbenzene Natural products CCC1=CC=CC=C1CC KVNYFPKFSJIPBJ-UHFFFAOYSA-N 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- JXHZRQHZVYDRGX-UHFFFAOYSA-M sodium;hydrogen sulfate;hydrate Chemical compound [OH-].[Na+].OS(O)(=O)=O JXHZRQHZVYDRGX-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9007483A FR2663330B1 (fr) | 1990-06-15 | 1990-06-15 | 0derives de 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxanes, leur preparation et leur application en therapeutique. |
| FR9104578A FR2675143B3 (fr) | 1991-04-15 | 1991-04-15 | Derives de 2-(aminoalkyl)-5-naphtyl-1,3-dioxanes, leur preparation et leur application en therapeutique. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PT97991A PT97991A (pt) | 1992-03-31 |
| PT97991B true PT97991B (pt) | 1998-11-30 |
Family
ID=26228078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97991A PT97991B (pt) | 1990-06-15 | 1991-06-14 | Processo para a preparacao de derivados de 2-(aminoalquil)-5-(arilalquil)-1,3-dioxanos e de composicoes farmaceuticas que os contem |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5192797A (cs) |
| EP (1) | EP0461958B1 (cs) |
| JP (1) | JPH0813808B2 (cs) |
| KR (1) | KR920000744A (cs) |
| AT (1) | ATE111460T1 (cs) |
| AU (1) | AU643290B2 (cs) |
| CA (1) | CA2044699A1 (cs) |
| CZ (1) | CZ280084B6 (cs) |
| DE (1) | DE69103968T2 (cs) |
| DK (1) | DK0461958T3 (cs) |
| ES (1) | ES2064057T3 (cs) |
| FI (1) | FI912888L (cs) |
| HU (1) | HU208432B (cs) |
| IE (1) | IE65067B1 (cs) |
| IL (1) | IL98454A (cs) |
| NO (1) | NO177995C (cs) |
| NZ (1) | NZ238557A (cs) |
| PL (1) | PL164840B1 (cs) |
| PT (1) | PT97991B (cs) |
| SK (1) | SK278142B6 (cs) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2714058B1 (fr) * | 1993-12-22 | 1996-01-19 | Synthelabo | Dérivés de 1,3-dioxane trisubstitués, leur préparation et leur application en thérapeutique. |
| FR2714055B1 (fr) * | 1993-12-22 | 1996-01-19 | Synthelabo | Dérivés de 5-(arylalkyl)-1,3-dioxane substitués en position 2, leur préparation et leur utilisation en thérapeutique. |
| FR2714056B1 (fr) * | 1993-12-22 | 1996-01-19 | Synthelabo | Dérivés de 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxane, leur préparation et leur application en thérapeutique. |
| FR2720939B1 (fr) * | 1994-06-08 | 1996-07-12 | Synthelabo | Utilisation de dérivés de N-[[5-(naphtalén-1-yl)-1,3-dioxan-2-yl]alkyl] acétamide pour la préparation de médicaments utiles dans le traitement des désordres neurodégénératifs. |
| FR2742152B1 (fr) * | 1995-12-06 | 1998-01-16 | Synthelabo | Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique |
| FR2764287B1 (fr) * | 1997-06-05 | 1999-07-16 | Synthelabo | Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique |
| PL337234A1 (en) * | 1997-06-05 | 2000-08-14 | Sanofi Synthelabo | Derivatives of 5-naphtalen-1-yl-1,3-dioxane, their production and therapeutic application |
| FR2843964B1 (fr) * | 2002-08-29 | 2004-10-01 | Sanofi Synthelabo | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique |
| GB2397067B (en) * | 2002-12-23 | 2005-05-11 | Destiny Pharma Ltd | Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation |
| EP1604654A1 (en) * | 2004-05-18 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating dyskinesia |
| GB2415372A (en) | 2004-06-23 | 2005-12-28 | Destiny Pharma Ltd | Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent |
| EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2016115504A1 (en) | 2015-01-15 | 2016-07-21 | Allaysis, Llc | Intravenous baclofen formulations and treatment methods |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1554878A (cs) * | 1967-12-12 | 1969-01-24 | ||
| US4116670A (en) * | 1977-04-04 | 1978-09-26 | Velsicol Chemical Company | Dioxane substituted amides |
| US4097491A (en) * | 1977-06-10 | 1978-06-27 | Velsicol Chemical Corporation | N-Dialkoxyalkyl-N-dioxanalkylene-α-haloalkanamides |
-
1991
- 1991-06-05 DK DK91401461.8T patent/DK0461958T3/da active
- 1991-06-05 DE DE69103968T patent/DE69103968T2/de not_active Expired - Lifetime
- 1991-06-05 EP EP91401461A patent/EP0461958B1/fr not_active Expired - Lifetime
- 1991-06-05 ES ES91401461T patent/ES2064057T3/es not_active Expired - Lifetime
- 1991-06-05 AT AT91401461T patent/ATE111460T1/de not_active IP Right Cessation
- 1991-06-11 IL IL9845491A patent/IL98454A/en not_active IP Right Cessation
- 1991-06-14 SK SK1837-91A patent/SK278142B6/sk unknown
- 1991-06-14 IE IE204591A patent/IE65067B1/en not_active IP Right Cessation
- 1991-06-14 US US07/714,182 patent/US5192797A/en not_active Expired - Fee Related
- 1991-06-14 PL PL91290676A patent/PL164840B1/pl unknown
- 1991-06-14 NO NO912298A patent/NO177995C/no unknown
- 1991-06-14 KR KR1019910009826A patent/KR920000744A/ko not_active Ceased
- 1991-06-14 AU AU78433/91A patent/AU643290B2/en not_active Ceased
- 1991-06-14 CA CA002044699A patent/CA2044699A1/en not_active Abandoned
- 1991-06-14 FI FI912888A patent/FI912888L/fi not_active Application Discontinuation
- 1991-06-14 NZ NZ238557A patent/NZ238557A/en unknown
- 1991-06-14 CZ CS911837A patent/CZ280084B6/cs unknown
- 1991-06-14 HU HU911992A patent/HU208432B/hu not_active IP Right Cessation
- 1991-06-14 JP JP3143090A patent/JPH0813808B2/ja not_active Expired - Lifetime
- 1991-06-14 PT PT97991A patent/PT97991B/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ238557A (en) | 1992-04-28 |
| IE912045A1 (en) | 1991-12-18 |
| NO912298D0 (no) | 1991-06-14 |
| PL164840B1 (pl) | 1994-10-31 |
| IL98454A0 (en) | 1992-07-15 |
| NO177995B (no) | 1995-09-25 |
| FI912888A0 (fi) | 1991-06-14 |
| US5192797A (en) | 1993-03-09 |
| AU7843391A (en) | 1991-12-19 |
| FI912888A7 (fi) | 1991-12-16 |
| CS183791A3 (en) | 1992-01-15 |
| KR920000744A (ko) | 1992-01-29 |
| IE65067B1 (en) | 1995-10-04 |
| ES2064057T3 (es) | 1995-01-16 |
| DK0461958T3 (da) | 1995-02-20 |
| EP0461958B1 (fr) | 1994-09-14 |
| DE69103968D1 (de) | 1994-10-20 |
| NO912298L (no) | 1991-12-16 |
| IL98454A (en) | 1996-07-23 |
| FI912888L (fi) | 1991-12-16 |
| CZ280084B6 (cs) | 1995-10-18 |
| ATE111460T1 (de) | 1994-09-15 |
| JPH04230277A (ja) | 1992-08-19 |
| PT97991A (pt) | 1992-03-31 |
| NO177995C (no) | 1996-01-03 |
| JPH0813808B2 (ja) | 1996-02-14 |
| SK278142B6 (en) | 1996-02-07 |
| AU643290B2 (en) | 1993-11-11 |
| HUT59124A (en) | 1992-04-28 |
| PL290676A1 (en) | 1991-12-16 |
| HU208432B (en) | 1993-10-28 |
| HU911992D0 (en) | 1991-12-30 |
| EP0461958A1 (fr) | 1991-12-18 |
| DE69103968T2 (de) | 1995-03-23 |
| CA2044699A1 (en) | 1991-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5731353A (en) | Stilbene derivatives and pharmaceutical compositions containing them | |
| EP0641767B1 (en) | Cytotoxic stilbene derivatives and pharmaceutical composition containing them | |
| EP0074304B1 (fr) | Ethers tricycliques, leur préparation et les compositions pharmaceutiques les contenant | |
| KR940003757B1 (ko) | 광학 활성 피리도벤즈옥사진 유도체의 제조방법 | |
| PT97991B (pt) | Processo para a preparacao de derivados de 2-(aminoalquil)-5-(arilalquil)-1,3-dioxanos e de composicoes farmaceuticas que os contem | |
| RU2109743C1 (ru) | Производные галантамина и фармацевтическая композиция | |
| EP0486386B1 (fr) | Nouveaux dérivés de la N-benzoyl proline, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| SU1356960A3 (ru) | Способ получени производных пиридазина | |
| JPS63502503A (ja) | 光学活性なアリルオキシプロパノ−ルアミン類及びアリルエタノ−ルアミン類の合成法 | |
| US4904690A (en) | Chromone derivatives useful as antitumor agents | |
| US4134991A (en) | Derivatives of 2-(3-phenyl-2-aminopropionyloxy)-acetic acid | |
| FR2623808A1 (fr) | Nouveaux derives flavonoides (benzyl-4 piperazinyl-1)-2 oxo-2 ethylene substitues, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent | |
| DE69806353T2 (de) | Pyrrolo[3,2-c]chinolin-derivate, die eine haloalkoxy-gruppe enthalten und ihre pharmazeutisch verträglichen salze | |
| RU2441867C2 (ru) | ПРОИЗВОДНЫЕ 5H-ДИБЕНЗО[b, e][1, 4]ДИАЗЕПИНА И ИХ ПРИМЕНЕНИЕ | |
| KR900004145B1 (ko) | 트리사이클릭 화합물의 제조방법 | |
| US5451606A (en) | Anthraquinone compounds useful to treat osteoarticular conditions, pharmaceutical compositions and method of treatment | |
| US3132176A (en) | Preparation of o, o-dialkanoyl derivatives of d, l-alpha-alkyl-beta-3, 4-dihydroxyphenylalanine by preferential acylation | |
| SU858570A3 (ru) | Способ получени производных 3-/тетразол-5-ил/-1-азаксантона или их солей | |
| CA1133483A (en) | Hexahydro-trans-pyridoindole neuroleptic agents | |
| RU1797611C (ru) | Способ разделени цис-3-амино-4-[2-(2-фурил)-эт-1-ил]-1-метоксикарбонилметил-азетидин-2-она на его энантиомерные компоненты | |
| US4670583A (en) | Amide compounds | |
| US3577409A (en) | 2-rch2nh-4-x-5-sulfamylbenzoic acids | |
| RU2067575C1 (ru) | 4-ацетил-5-п-иодфенил-1-карбоксиметил-3-гидрокси-2,5-дигидропиррол-2-он, проявляющий анальгетическую активность | |
| FR2660310A1 (fr) | Nouveaux derives de la 4h-pyrrolo[1,2a] thieno[2,3-f] diazepine[1,4], leur procede de preparation et les compositions pharmaceutiques les renfermant. | |
| US3833728A (en) | Indole derivatives in the treatment of skeletal muscle fatigability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB1A | Laying open of patent application |
Effective date: 19911114 |
|
| FG3A | Patent granted, date of granting |
Effective date: 19980824 |
|
| MM3A | Annulment or lapse |
Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20000229 |